Uti

© Jomkwan / Getty Images

GSK picks up antibiotic in $66m deal

By Ben Hargreaves

GSK pays for the exclusive license of Spero‘s late-stage antibiotic to potentially treat complicated urinary tract infections.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All